Zepbound Pre-Surgery Hold Window: How Long to Stop Tirzepatide Before an Operation

Why the Pre-Surgery Hold Matters for Zepbound

Tirzepatide slows gastric emptying significantly, and that effect does not simply switch off overnight. Standard nil-per-os (NPO) fasting guidelines assume normal gastric motility. When motility is suppressed, food and liquid can remain in the stomach well past the 8-hour solid-food cutoff, creating a documented aspiration hazard under general anesthesia.

The Gastric-Emptying Mechanism

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. The GLP-1 component slows gastric emptying through vagal pathways, an effect that is dose-dependent and persists for days after the last injection. Gastric-emptying scintigraphy studies show that GLP-1 receptor agonists reduce the gastric emptying rate by 20 to 40 percent compared with placebo, with effects measurable at 4 hours post-meal. Tirzepatide's pharmacodynamic profile in phase 1 studies confirmed that gastric emptying slowing persists throughout the weekly dosing interval, not just on injection day.

Why Aspiration Risk Is Real

Pulmonary aspiration of gastric contents carries a case-fatality rate of approximately 5 percent in perioperative settings, based on a large case series reviewed by the ASA. Patients on GLP-1 receptor agonists may present with a "full stomach" phenotype even after an apparently adequate fast. A 2023 case-series letter in Anaesthesia described residual solid gastric contents detected by ultrasound in GLP-1 agonist users who fasted the standard 6 to 8 hours. These findings prompted the formal ASA guidance issued later that year.

Current Guidelines on Holding GLP-1 Agonists Before Surgery

The American Society of Anesthesiologists 2023 consensus guidance is the most widely cited document in U.S. Practice. It applies to all GLP-1 receptor agonists, including tirzepatide, semaglutide (Ozempic, Wegovy), and liraglutide (Victoza, Saxenda).

ASA 2023 Recommendations

For patients on weekly GLP-1 or dual GIP/GLP-1 agonist dosing (which includes tirzepatide 5 mg, 10 mg, and 15 mg), the ASA recommends:

• Skip the dose on the day of surgery for daily formulations.
• Skip one full weekly dose before elective procedures for weekly formulations, meaning the last dose is taken 7 or more days before surgery.
• If GI symptoms such as nausea, vomiting, or abdominal bloating are present on the day of surgery regardless of the hold period, consider delaying the procedure or treating the patient as a full-stomach case with rapid-sequence induction.

The ASA guidance states directly: "For patients with GI symptoms (nausea, vomiting, dyspepsia, abdominal distension), the GLP-1 RA should be held for longer periods, up to a week for daily dosing and up to 4 weeks for weekly dosing, prior to elective procedures." This document is available in full at the ASA newsroom.

Society for Obesity and Bariatric Anesthesia Position

The Society for Obesity and Bariatric Anesthesia (SOBA) issued a compatible position statement recommending point-of-care gastric ultrasound for all patients on GLP-1 agonists presenting for surgery, even after a guideline-compliant hold. Gastric antral cross-sectional area above 10 cm² in the right-lateral decubitus position is used as a threshold for classifying a patient as high-risk for aspiration. This additive monitoring step is particularly relevant for bariatric patients already on tirzepatide for obesity management.

European Perspective

The European Society of Anaesthesiology and Intensive Care (ESAIC) published guidance in late 2023 aligned with the ASA position. For weekly GLP-1 agonists, ESAIC recommends a minimum 1-week hold and individualizing extended holds based on GI symptom burden. The ESAIC language is notably similar: both documents emphasize that standard fasting times were derived before GLP-1 agonist use was widespread and may not apply to this population.

Tirzepatide's Pharmacokinetics and What They Mean for Surgical Timing

Tirzepatide has a terminal half-life of approximately 5 days. The prescribing information filed with FDA reports peak plasma concentration at 8 to 72 hours after subcutaneous injection, with steady-state reached after 4 weeks of weekly dosing. At steady-state, the mean accumulation ratio is approximately 4-fold compared with a single dose.

One Week vs. Four Weeks: What Drives the Decision

Holding for 1 week (one missed dose) allows plasma tirzepatide to fall to roughly 50 percent of peak based on the 5-day half-life. That may be sufficient for gastric motility to partially normalize in patients without symptoms. A pharmacokinetic modeling study found that GLP-1-mediated gastric-emptying effects lag behind plasma drug levels, meaning motility may remain suppressed even as plasma concentrations decline. Patients with active GI symptoms, who are likely to have more pronounced vagal suppression, may need 2 to 4 weeks for measurable motility recovery.

A 4-week hold brings plasma concentration to approximately 6 percent of steady-state. That is the rationale behind the extended hold recommendation for symptomatic patients. No randomized controlled trial has yet directly compared 1-week vs. 4-week holds on aspiration outcomes, a gap that current literature openly acknowledges. One 2024 systematic review in Obesity Reviews called for prospective data on the optimal perioperative hold duration across GLP-1 drug classes.

Daily vs. Weekly Formulations

Tirzepatide is currently only available in a weekly subcutaneous formulation. This differs from liraglutide (daily) and from the once-weekly oral semaglutide in the Rybelsus format. Because tirzepatide's weekly schedule means each dose builds on a substantial drug reservoir, the pharmacokinetic argument for a longer hold period relative to daily drugs is straightforward. FDA label data confirm that after a single missed weekly dose at steady-state, trough concentrations remain clinically active for several days.

SURMOUNT-1 Context: Why Patients Are on Tirzepatide in the First Place

Understanding why patients may be reluctant to pause therapy requires knowing the magnitude of benefit tirzepatide provides. In SURMOUNT-1 (N=2,539, NEJM 2022), tirzepatide 15 mg produced a mean body-weight loss of 20.9 percent at 72 weeks versus 3.1 percent with placebo (P<0.0001). The 10 mg dose produced 19.5 percent loss and the 5 mg dose produced 15.0 percent loss.

Weight Regain During Holds

SURMOUNT-4 (NEJM 2023) demonstrated that patients who discontinued tirzepatide after 36 weeks of open-label treatment regained 14 percentage points of their lost weight by week 88 compared to those who continued. A 1-to-4-week surgical hold is unlikely to produce meaningful weight regain, but this trial provides the mechanistic backdrop for patient anxiety about stopping the drug. Providers should reassure patients that a short perioperative hold does not erase their progress.

Metabolic Improvements at Stake

Tirzepatide's glucose-lowering effects disappear more quickly than its weight effects after discontinuation. A post-hoc analysis of SURPASS-2 data showed that HbA1c benefits begin reversing within 4 weeks of stopping in patients with type 2 diabetes. For surgical patients with comorbid T2DM, the surgical team should plan for closer perioperative glucose monitoring during the hold period. Target intraoperative glucose is 140 to 180 mg/dL per Society of Thoracic Surgeons guidelines.

Practical Protocol: Stopping and Restarting Zepbound Around Surgery

This section outlines a four-phase perioperative protocol. No single published guideline captures all four phases explicitly; this framework synthesizes ASA 2023, ESAIC 2023, SOBA guidance, and FDA prescribing information into a clinically actionable sequence.

Phase 1: Pre-Operative Medication Review (4 to 6 Weeks Before Surgery)

At the surgical workup visit, the prescribing clinician and anesthesiologist should jointly decide on hold duration. The decision tree has three branches:

1. Asymptomatic, weekly tirzepatide dose: Hold 1 week (skip one dose). Last dose no less than 7 days before surgery.
2. GI symptoms (nausea, reflux, dyspepsia, bloating), weekly dose: Hold 2 to 4 weeks. Last dose no less than 14 to 28 days before surgery.
3. Poorly controlled T2DM on tirzepatide as primary antihyperglycemic: Consider holding 2 weeks minimum and bridging with insulin per endocrinology. ADA Standards of Care 2024 recommends individualized perioperative glucose management.

Phase 2: Day-of-Surgery Assessment

Even after a compliant hold, the anesthesiologist should assess for residual GI symptoms. Gastric ultrasound of the antrum in the right-lateral decubitus position takes under 5 minutes and has a sensitivity of approximately 85 percent for detecting a full stomach. Antral cross-sectional area above 10 cm² should trigger rapid-sequence induction regardless of documented fasting time.

Phase 3: Intraoperative and Recovery Management

For patients treated as full-stomach cases, standard RSI with cricoid pressure and early confirmation of gastric emptying via orogastric tube is appropriate. Anesthesiology practice guidelines advise that aspiration precautions should not be relaxed until there is direct evidence of a cleared gastric field.

Phase 4: Restarting Tirzepatide After Surgery

Tirzepatide may be restarted once the patient tolerates oral intake and surgical healing is progressing normally, typically 1 to 2 weeks post-operation for elective procedures. Wound-healing data from SURMOUNT-1 do not suggest that tirzepatide impairs healing; however, post-bariatric patients face altered pharmacokinetics due to changes in GI anatomy. A 2022 review in Obesity Surgery noted that subcutaneous absorption of GLP-1 agonists is not materially changed by Roux-en-Y anatomy, making restart dosing similar to pre-surgical protocols.

Special Populations: Bariatric, Cardiac, and Endoscopic Procedures

Not all surgeries carry the same aspiration risk profile, and hold-window decisions should be procedure-specific.

Bariatric Surgery Patients

Patients on tirzepatide for obesity who are proceeding to bariatric surgery represent a nuanced case. A 2023 retrospective cohort study (N=184) found that pre-operative GLP-1 agonist use was associated with higher rates of intraoperative gastric content identification during sleeve gastrectomy, supporting the extended hold recommendation for this population. The American Society for Metabolic and Bariatric Surgery (ASMBS) has incorporated GLP-1 hold language into its pre-operative checklist updates.

Cardiac and Non-Abdominal Procedures

The gastric-emptying effect of tirzepatide is systemic and not limited to abdominal surgeries. A patient undergoing total knee replacement or coronary artery bypass grafting faces the same aspiration risk if on tirzepatide. An editorial in the British Journal of Anaesthesia specifically cautioned against assuming cardiac surgical teams were outside the scope of the GLP-1 guidance.

Endoscopic Procedures Requiring Sedation

Upper GI endoscopy and colonoscopy under propofol sedation carry lower airway-management risk than general anesthesia, but aspiration remains possible. ACG practice guidelines recommend applying the same GLP-1 hold considerations to endoscopy, with a minimum 1-week hold for weekly agents. The gastroenterology team performing the procedure should be notified of GLP-1 agonist use during the consent and pre-procedure documentation process.

Communicating the Hold to Patients

Patient adherence to the hold window depends on clear communication. Patients with significant weight loss on tirzepatide are often reluctant to miss even one dose. A survey study of GLP-1 agonist users (N=312) found that 38 percent were unaware that GLP-1 agents required any pre-surgical modification, and 22 percent reported they would skip the surgeon's advice to hold the drug.

Three communication points tend to improve adherence:

• Explaining that a 1-to-4-week hold does not reverse the plateau of weight loss already achieved, based on SURMOUNT-4 kinetics.
• Clarifying that the risk is anesthesia-specific and not a sign the drug is harmful.
• Providing a written stop date tied to the specific scheduled surgery date, rather than a general instruction to "hold before surgery."

The prescribing telehealth provider, the anesthesiologist, and the surgeon should all document the agreed hold plan in the medical record to prevent conflicting instructions at the time of pre-operative admission.

Emerging Data and Unresolved Questions

The evidence base for GLP-1 perioperative hold windows is evolving rapidly. Several issues remain without definitive trial data.

Gastric Ultrasound as Standard of Care

Point-of-care gastric ultrasound is not yet universally available. A 2023 Anesthesiology survey (N=447 anesthesiologists) found that only 31 percent of U.S. Training programs had incorporated gastric ultrasound into their GLP-1 perioperative protocol. Until adoption is broader, the hold-window policy functions as the primary safety backstop.

Prokinetic Pre-Treatment as an Alternative

Some centers have explored pre-operative metoclopramide or erythromycin to accelerate gastric emptying in GLP-1 agonist users who cannot safely hold the drug. A small feasibility study (N=28) found that 10 mg IV metoclopramide given 30 minutes before induction reduced residual gastric volume in GLP-1 users, but the sample size was too small to draw safety conclusions. This approach is investigational and not part of any formal guideline as of mid-2025.

Optimal Hold Duration by Dose Tier

The 1-week vs. 4-week binary does not account for dose differences within tirzepatide's own dosing ladder. A patient on 5 mg tirzepatide has a lower peak plasma level than one on 15 mg, and a correspondingly lower degree of gastric-emptying suppression. Pharmacokinetic simulation data from the FDA clinical pharmacology review suggest that the gastric-motility effect at 5 mg is approximately 60 percent of the effect at 15 mg. Dose-stratified hold windows have not yet been formally adopted in any published guideline, but the pharmacokinetic rationale supports future refinement.